Sacco S, Lampl C, van den Maassen A, Caponnetto V, Braschinsky M, Ducros A et al (2021) Burden and attitude to resistant and refractory migraine: a survey from the European Headache Federation with the endorsement of the European Migraine & Headache Alliance. J Headache Pain 22:39

Article  PubMed  PubMed Central  Google Scholar 

Schulman EA, Brahin EJ (2008) Refractory headache: historical perspective, need, and purposes for an operational definition. Headache 48:770–777

Article  PubMed  Google Scholar 

Schulman EA, Peterlin BL, Lake AE 3rd, Lipton RB, Hanlon A, Siegel S et al (2009) Defining refractory migraine: results of the RHSIS Survey of American Headache Society members. Headache 49:509–518

Article  PubMed  Google Scholar 

D’Antona L, Matharu M (2019) Identifying and managing refractory migraine: barriers and opportunities? J Headache Pain 20:89

Article  PubMed  PubMed Central  Google Scholar 

Sacco S, Braschinsky M, Ducros A, Lampl C, Little P, van den Brink AM et al (2020) European headache federation consensus on the definition of resistant and refractory migraine: developed with the endorsement of the European Migraine & Headache Alliance (EMHA). J Headache Pain 21:76

Article  PubMed  PubMed Central  Google Scholar 

Gonzalez-Martinez A, Sanz-García A, García-Azorín D, Rodríguez-Vico J, Jaimes A, Gómez García A et al (2024) Effectiveness, tolerability, and response predictors of preventive anti-CGRP mAbs for migraine in patients over 65 years old: a multicenter real-world case-control study. Pain Med 25:194–202

Article  PubMed  Google Scholar 

Sánchez-Rodríguez C, Gago-Veiga AB, García-Azorín D, Guerrero-Peral ÁL, Gonzalez-Martinez A (2023) Potential predictors of response to CGRP monoclonal antibodies in chronic migraine: real-World Data. Current Pain and Headache Reports

Lee HC, Cho S, Kim B-K (2023) Predictors of response to galcanezumab in patients with chronic migraine: a real-world prospective observational study. Neurol Sci 44:2455–2463

Article  PubMed  Google Scholar 

Radat F (2021) What is the link between migraine and psychiatric disorders? From epidemiology to therapeutics. Rev Neurol (Paris) 177:821–826

Article  CAS  PubMed  Google Scholar 

Baraldi C, Castro FL, Cainazzo MM, Pani L, Guerzoni S (2021) Predictors of response to erenumab after 12 months of treatment. Brain Behav 11:e2260

Article  PubMed  PubMed Central  Google Scholar 

Ihara K, Ohtani S, Watanabe N, Takahashi N, Miyazaki N, Ishizuchi K et al (2023) Predicting response to CGRP-monoclonal antibodies in patients with migraine in Japan: a single-centre retrospective observational study. J Headache Pain 24:23

Article  CAS  PubMed  PubMed Central  Google Scholar 

Caronna E, Gallardo VJ, Egeo G, Vázquez MM, Castellanos CN, Membrilla JA et al (2024) Redefining migraine prevention: early treatment with anti-CGRP monoclonal antibodies enhances response in the real world.jnnp-2023-333295

Ahmed F, Cheng F, Wu Q, Hussain M, Wilkinson V, Wilson L et al (2022) Efficacy of fremanezumab in refractory chronic migraine patients: real-world data from the Hull Migraine Clinic, UK. Research Square

(2013) The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia. 33:629–808

Yang M, Rendas-Baum R, Varon SF, Kosinski M (2011) Validation of the Headache Impact Test (HIT-6™) across episodic and chronic migraine. Cephalalgia 31:357–367

Article  PubMed  PubMed Central  Google Scholar 

Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67:361–370

Article  CAS  PubMed  Google Scholar 

Stewart WF, Lipton RB, Dowson AJ, Sawyer J (2001) Development and testing of the Migraine Disability Assessment (MIDAS) Questionnaire to assess headache-related disability. Neurology 56:S20–28

Article  CAS  PubMed  Google Scholar 

Morin CM, Belleville G, Bélanger L, Ivers H (2011) The Insomnia Severity Index: psychometric indicators to detect insomnia cases and evaluate treatment response. Sleep 34:601–608

Article  PubMed  PubMed Central  Google Scholar 

Lipton RB, Cohen JM, Galic M, Seminerio MJ, Yeung PP, Aycardi E et al (2021) Effects of fremanezumab in patients with chronic migraine and comorbid depression: subgroup analysis of the randomized HALO CM study. Headache 61:662–672

Article  PubMed  PubMed Central  Google Scholar 

Dodick DW (2009) Review of comorbidities and risk factors for the development of migraine complications (infarct and chronic migraine). Cephalalgia 29 Suppl 3:7–14

Google Scholar 

Buse DC, Greisman JD, Baigi K, Lipton RB (2019) Migraine progression: a systematic review. 59:306–338

Ornello R, Andreou AP, De Matteis E, Jürgens TP, Minen MT, Sacco S (2024) Resistant and refractory migraine: clinical presentation, pathophysiology, and management. eBioMedicine. 99

Schiano di Cola F, Caratozzolo S, Liberini P, Rao R, Padovani A (2019) Response Predictors in Chronic Migraine: Medication Overuse and Depressive Symptoms Negatively Impact Onabotulinumtoxin-A Treatment. 10

Hong JB, Lange KS, Overeem LH, Triller P, Raffaelli B, Reuter U (2023) A scoping review and Meta-analysis of Anti-CGRP monoclonal antibodies: Predicting Response. Pharmaceuticals (Basel). 16

Do TP, Heldarskard GF, Kolding LT, Hvedstrup J, Schytz HW (2018) Myofascial trigger points in migraine and tension-type headache. J Headache Pain 19:84

Article  PubMed  PubMed Central  Google Scholar 

Giamberardino MA, Tafuri E, Savini A, Fabrizio A, Affaitati G, Lerza R et al (2007) Contribution of myofascial trigger points to migraine symptoms. J Pain 8:869–878

Article  PubMed  Google Scholar 

de Tommaso M, Sciruicchio V (2016) Migraine and central sensitization: clinical features, main comorbidities and therapeutic perspectives. Curr Rheumatol Rev 12:113–126

Article  PubMed  Google Scholar 

Latremoliere A, Woolf CJ (2009) Central sensitization: a generator of pain hypersensitivity by central neural plasticity. J Pain 10:895–926

Article  PubMed  PubMed Central  Google Scholar 

Conceição HNS, Azevêdo TC, Santos ACdJd, Xavier MRSR (2022) Comorbidities associated with temporomandibular joint disorders and the role of central sensitization: literature review. BrJP. 5

Teruel A, Romero-Reyes M (2022) Interplay of oral, mandibular, and Facial disorders and Migraine. Curr Pain Headache Rep 26:517–523

Article  PubMed  Google Scholar 

Perry SK, Emrick JJ (2024) Trigeminal somatosensation in the temporomandibular joint and associated disorders. 5

Pelzer N, de Boer I, van den Maagdenberg A, Terwindt GM (2023) Neurological and psychiatric comorbidities of migraine: concepts and future perspectives. Cephalalgia 43:3331024231180564

Article  PubMed  Google Scholar 

Rubino E, Rainero I, Garino F, Vicentini C, Govone F, Vacca A et al (2019) Subclinical hypothyroidism is associated with migraine: a case-control study. Cephalalgia 39:15–20

Article  PubMed  Google Scholar 

Tasnim S, Wilson SG, Walsh JP, Nyholt DR (2023) Shared genetics and causal relationships between migraine and thyroid function traits. Cephalalgia 43:3331024221139253

Article  PubMed  Google Scholar 

Torres-Ferrús M, Ursitti F, Alpuente A, Brunello F, Chiappino D, de Vries T et al (2020) From transformation to chronification of migraine: pathophysiological and clinical aspects. J Headache Pain 21:42

Article  PubMed  PubMed Central  Google Scholar 

Minen MT, De Begasse O, Van Kroon A, Powers S, Schwedt TJ, Lipton R et al (2016) Migraine and its psychiatric comorbidities. J Neurol Neurosurg Psychiatry 87:741–749

Article  PubMed  Google Scholar 

Mantonakis L, Belesioti I, Deligianni CI, Natsis V, Mitropoulou E, Kasioti E et al (2024) Depression and anxiety symptoms in Headache disorders: an Observational, cross-sectional study. Neurol Int 16:356–369

Article  PubMed  PubMed Central  Google Scholar 

D’Amico D, Sansone E, Grazzi L, Giovannetti AM, Leonardi M, Schiavolin S et al (2018) Multimorbidity in patients with chronic migraine and medication overuse headache. Acta Neurol Scand 138:515–522

Article  PubMed  Google Scholar 

Bigal ME, Lipton RB, Holland PR, Goadsby PJ (2007) Obesity, migraine, and chronic migraine: possible mechanisms of interaction. Neurology 68:1851–1861

Article  PubMed  Google Scholar 

Bigal ME, Liberman JN, Lipton RBJN (2006) Obesity and migraine: a population study. 66:545–550

de Vries Lentsch S, van der Arend BWH, de Boer I, van Zwet EW, MaassenVanDenBrink A, Terwindt GM (2024) Depression and treatment with anti-calcitonin gene related peptide (CGRP) (ligand or receptor) antibodies for migraine. Eur J Neurol 31:e16106

Article  PubMed  Google Scholar 

Maasumi K, Thompson NR, Kriegler JS, Tepper SJ (2015) Effect of OnabotulinumtoxinA injection on Depression in Chronic Migraine. Headache 55:1218–1224

Article  PubMed  Google Scholar 

Martin PR, Aiello R, Gilson K, Meadows G, Milgrom J, Reece J (2015) Cognitive